Introduction Patient-reported smoking history is frequently used as a stratification factor in
NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the …

Oncogenic mutations within the EGFR kinase domain are well-established driver mutations
in non–small cell lung cancer (NSCLC). Small-molecule tyrosine kinase inhibitors (TKIs) …

Background Osimertinib represents the standard of care for the treatment of advanced non-
small-cell lung cancer (NSCLC) harboring classical epidermal growth factor receptor …

Next‐generation sequencing (NGS) assays can sensitively detect somatic variation, and
increasingly can enable the identification of complex structural rearrangements. A subset of …

Background EGFR kinase domain duplication (EGFR-KDD) is an infrequent oncogenic
driver mutation in lung adenocarcinoma. It may be a potential target benefit from EGFR …

Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare, recurrent
oncogenic variant that constitutively activates EGFR in non-small-cell lung cancer. Herein …

Purpose Epidermal growth factor receptor kinase domain duplication (EGFR-KDD) is a rare
and poorly understood oncogenic mutation in non–small cell lung cancer (NSCLC). We …

Epidermal growth factor receptor (EGFR) kinase domain duplication (KDD) has been
identified as an oncogenic driver in 0.05% to 0.14% of non–small cell lung cancer (NSCLC) …

Precision cancer care, for essentially all cancer types, now requires molecular diagnostics to
assess mutations, chromosomal alterations, and gene expression to personalize treatments …

Introduction: Patient-reported smoking history is frequently used as a stratification factor in
NSCLC-directed clinical research. Nevertheless, this classification does not fully reflect the …